PPARα/γ dual agonists (e.g., glitazar) and PPARα/δ dual agonists (e.g., elafibranor) have been developed for clinical use in adults with primary biliary cholangitis, and pan-PPAR agonists are under Phase III clinical trials for nonalcoholic steatosis (e.g., lanifibranor, a PPARα/γ/δ agonist) [23]. Here, PPARA is linked to primary biliary cholangitis.